A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML
Latest Information Update: 17 Oct 2022
At a glance
- Drugs Decitabine (Primary) ; Panobinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON 116 AML
- Sponsors Janssen-Cilag; Novartis
- 16 Oct 2022 This trial has been completed in Netherlands (End Date: 2 Aug 2022) according to European Clinical Trials Database record.
- 06 Dec 2016 Interim results (n=54) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.